Browse the evidence

High cost or insurance-related barriers are the primary drivers of discontinuation for obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice, accounting for nearly half of all early and late discontinuations.

If you are stopping semaglutide or tirzepatide, the most likely reason is cost or insurance issues, not that the drug didn't work. Check your insurance coverage, look for manufacturer coupons, and talk to your doctor about financial assistance programs before assuming the treatment is unsuitable for you.

Long-term use of GLP-1 receptor agonists (≥78 weeks) significantly increases the risk of deep vein thrombosis (DVT) compared to placebo or other anti-diabetic drugs.

If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Victoza) for more than a year, be aware that your risk of deep vein thrombosis (DVT) is higher than if you were not taking it. This risk is most notable in people with existing cardiovascular disease. However, the absolute increase in risk is small. Discuss any history of blood clots with your doctor before starting or continuing long-term therapy.

Overall Venous Thromboembolism (VTE) risk is not significantly increased by GLP-1RA use, as the increase in DVT is offset by no change in Pulmonary Embolism (PE) risk.

Taking GLP-1 medications does not significantly increase your overall risk of blood clots (VTE) when looking at the big picture. While there is a small, non-significant upward trend, it is not statistically proven to be dangerous for the general population. The specific risk of DVT is only significant with very long-term use.

BMI is an inadequate and potentially harmful sole metric for assessing obesity severity and treatment response.

Do not rely on BMI alone. Your health is determined by your metabolic markers and fat distribution, not just your weight. Seek a comprehensive assessment that looks at your overall health risks.

Among adults with diabetes, higher BMI (overweight and obese categories) is not associated with increased all-cause mortality compared to normal weight, contradicting the U-shaped mortality curve observed in the general population.

For people with diabetes, maintaining a 'normal' BMI (18.5-24.9) does not necessarily confer a mortality advantage over being overweight or obese, based on this large US study. However, this does not mean obesity is 'healthy.' It suggests that other factors like glycemic control (HbA1c), blood pressure, and smoking status are critical. Patients should focus on overall metabolic health rather than just weight loss, especially if they have been diagnosed with diabetes for a while.

Among people with diabetes and high glycemic control (HbA1c ≥7.1%), overweight BMI (25-29.9 kg/m2) is associated with significantly lower mortality risk compared to normal weight BMI.

If you have diabetes and your blood sugar levels are consistently high (HbA1c ≥7.1%), being slightly overweight (BMI 25-29.9) might actually be associated with a lower risk of death compared to being normal weight. This does not mean you should gain weight, but it suggests that aggressive weight loss might not be the primary goal for everyone with poorly controlled diabetes. Focus on stabilizing your blood sugar and overall health.

Global average total protein intake (78.2 g/day) exceeds the minimum requirement for health in all surveyed countries, with national means never falling below 46 g/day, indicating that protein deficiency is not a widespread global issue in terms of quantity.

You do not need to worry about global protein shortages or your personal intake being critically low if you eat a standard diet. The global average is 78g/day, and even the lowest-consuming nations average 46g/day, which is sufficient. Focus on the source (animal vs. plant) and overall diet quality rather than fearing protein deficiency.

GLP-1 medicines for obesity are predominantly tested in white/Caucasian populations (79%) with significant under-representation of non-white, Black, Asian, and Indigenous groups compared to their prevalence in multiethnic national populations.

Current GLP-1 obesity trials heavily feature white participants (79%). If you belong to a racial or ethnic minority, be aware that the standard dosing and efficacy data may not fully reflect your specific physiological response or risk profile. Advocating for or seeking out diverse clinical data is important for personalized care.

GLP-1 obesity trials are geographically concentrated in high-income countries (84.2% of sites), contrasting with the global prevalence of obesity which is highest in low- and middle-income countries (LMICs).

Most GLP-1 trials were conducted in high-income countries, yet most people with obesity live in low- and middle-income countries. This geographic gap means that treatment guidelines and availability may not reflect the needs of the majority of the global population.

SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors provide cardiovascular organ protection in type 2 diabetes through direct antioxidant and anti-inflammatory mechanisms, independent of glucose lowering.

If you have Type 2 Diabetes, ask your doctor about SGLT2 inhibitors or GLP-1 agonists. These drugs do more than just lower blood sugar; they actively protect your heart and kidneys by reducing inflammation and oxidative stress, which are major drivers of heart disease in diabetic patients.

GLP-1 receptor agonists reduce platelet aggregation and thrombus formation, thereby mitigating the risk of thrombotic cardiovascular events in diabetic patients.

GLP-1 agonists may help prevent blood clots by making platelets less sticky, which adds to their heart-protective benefits beyond just sugar control.

Intestinal deficiency of Acyl-CoA synthetase 5 (ACSL5) reduces food intake and protects against diet-induced obesity by increasing postprandial secretion of GLP-1 and PYY.

This research suggests that how your body processes dietary fat in the intestine—specifically through the enzyme ACSL5—can influence your hunger hormones (GLP-1 and PYY). When this process is altered, it can lead to increased feelings of fullness and reduced food intake, potentially protecting against weight gain on high-fat diets. While this is a genetic mechanism in mice, it highlights the importance of gut hormones in regulating appetite and energy balance.

Semaglutide (2.4 mg weekly) induces MASH resolution in patients with stage 2-3 fibrosis, though it does not significantly improve fibrosis itself.

Semaglutide 2.4 mg weekly is highly effective at resolving active liver inflammation (MASH) in patients with moderate fibrosis. However, it does not reverse the scarring (fibrosis) itself. Patients should expect significant weight loss and metabolic improvement, but should not assume their liver scarring will disappear with this drug alone.

Statins reduce the risk of developing MASLD and progression to liver fibrosis, and may reduce cardiovascular events in MASLD patients, despite not directly reducing liver fat.

If you have fatty liver and high cardiovascular risk, you should take statins. They do not remove liver fat, but they reduce inflammation and fibrosis, and significantly lower your risk of heart attacks and strokes. The benefits outweigh the theoretical risks.

Pioglitazone improves MASH resolution and may improve fibrosis, but is limited by side effects like weight gain and heart failure exacerbation.

Pioglitazone can resolve MASH and improve fibrosis, but it causes weight gain and fluid retention, which can worsen heart failure. It is not a first-line treatment but may be considered if other options fail and heart failure is not a concern.

Once-weekly semaglutide treatment is associated with a significant increase in pulse rate compared to once-daily sitagliptin.

If you take semaglutide, expect your resting heart rate to increase slightly (by about 3 beats per minute) compared to if you took sitagliptin. This is a known side effect. While usually not dangerous, it is worth monitoring, especially if you have underlying heart conditions.

Semaglutide treatment is associated with a higher risk of total adverse events and premature treatment discontinuation compared to sitagliptin, although the risk of serious adverse events is not significantly different.

Be prepared for a higher likelihood of side effects and stopping the medication early when starting semaglutide compared to sitagliptin. Most side effects are gastrointestinal. Slow dose escalation can help. However, serious adverse events are not significantly more common with semaglutide.

Rapid and substantial weight reduction, such as that achieved by bariatric surgery or certain medications, may result in greater reductions in lean muscle mass compared to gradual weight reduction.

If you are undergoing rapid weight loss (e.g., surgery or strong medications), prioritize resistance training and adequate protein intake to protect your muscle mass. Monitor your body composition, not just scale weight, to ensure you are losing fat, not muscle.

GLP-1 receptor agonists increase the risk of gallbladder disease, including cholelithiasis and cholecystitis, through mechanisms involving cholecystokinin (CCK) suppression, altered bile acid receptor signaling (FXR/TGR5), and disrupted gut-brain pathways, leading to bile stasis and gallstone formation.

If you are taking a GLP-1 agonist (like semaglutide or liraglutide), be aware that you have a higher risk of gallbladder problems, especially if you are taking higher doses or losing weight rapidly. Watch for symptoms like severe abdominal pain, nausea, or fever, and report them to your doctor immediately. Your doctor may monitor you more closely or adjust your treatment plan to mitigate this risk.

Activation of brown and beige adipose tissue through pharmacological means (e.g., β3-AR agonists, GLP-1RAs) or transplantation improves glucose metabolism, insulin sensitivity, and energy expenditure, offering a therapeutic strategy for obesity and type 2 diabetes.

Your body has a biological mechanism to burn extra energy as heat using brown and beige fat. While cold exposure and exercise can activate this, pharmaceutical approaches (like mirabegron or GLP-1 agonists) are being studied to enhance this process. This suggests that metabolic health is not just about calories in/out but also about the activity of specific fat tissues.

Mathematical models of body weight dynamics accurately predict average weight loss in compliant patients, but individual prediction precision is fundamentally limited by uncertainty in baseline energy requirements and physical activity changes.

Use dynamic weight loss models to set realistic expectations and track progress, but understand that individual results will vary. If you are adhering to a plan but not losing weight as predicted, it may be due to your unique baseline metabolism or activity changes, not just 'cheating'. Use the model's predicted range to discuss barriers with your clinician rather than assuming failure.

Intensive dietary counseling targeting sodium reduction to <2.3 g/day fails to sustainably reduce sodium intake, blood pressure, or cardiorenal biomarkers in individuals with moderate baseline sodium intake over a two-year period.

If you currently eat a moderate amount of sodium (around 3 grams/day), trying to drastically cut it down to less than 2.3 grams through intense counseling is unlikely to work long-term. You might see a small, short-term drop in blood pressure, but it won't last, and it won't improve your heart or kidney health markers. The effort required to maintain such a low intake is likely too high for sustainable results in this group.

Adherence to liraglutide 3.0 mg for obesity treatment is extremely low (84.9% of patients exhibit low adherence), with only 15.1% achieving high adherence (PDC ≥80%) after 6 months.

If you are prescribed liraglutide 3.0 mg for weight loss, expect that most people stop taking it consistently within 6 months. High adherence (taking it daily as prescribed) is rare (15%). To succeed, you must actively manage side effects and address the burden of daily injections, possibly with dietitian support, as these are key predictors of sticking with the treatment.

Biased agonism of GLP-1R and GIPR (favoring cAMP over beta-arrestin recruitment) yields superior glucose lowering, food intake suppression, and weight loss compared to unbiased agonism.

Current GLP-1/GIP drugs that favor cAMP signaling (biased) appear to offer better and longer-lasting glucose control and weight loss than those that do not. This is likely due to the drug staying on the receptor longer without being internalized. While this is proven in mice, it suggests that drug design matters for efficacy, not just receptor activation.